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comes were assessed for perioperative adverse cardiac events including death, STEMI,
NSTEMI, stent thrombosis, and target vessel revascularization (TVR). NSTEMI was
defined by meeting 2 of the following criteria: Chest pain > 30 minutes, new ECG
changes consistent with ischemia and troponin or CK-MB elevation > 2 times the upper
limit of normal. Major bleeding, defined as postoperative transfusion or need for reopera-
tion, was also assessed.
Results: The study population consisted of 32 men and 14 women with a mean age of
68 years. 37% of patients had diabetes. PCI was successful and uncomplicated in all
patients. A total of 58 lesions were treated with 62 stents, of which 55% were heparin
coated. Clopidogrel was stopped at a median of 6 days prior to surgery. Following NCS,
there were no deaths, STEMI or stent thrombosis. The only perioperative complication
was one NSTEMI (2.2%) which led to TVR of a new lesion. Two patients (4.3%) required
postoperative blood transfusion.
Conclusion: NCS can be safely performed after coronary stenting utilizing a therapeutic
strategy of deferring surgery for greater than 5 weeks, discontinuing clopidogrel before-
hand, and using heparin coated stents in high-risk patients.
1063-54 Long-Term Clopidogrel Therapy Is Particularly 
Beneficial for Patients Requiring Repeat 
Revascularization After an Initial Percutaneous 
Coronary Intervention
Jacqueline Saw, Eric J. Topol, Steven R. Steinhubl, Danielle Brennan, Peter B. Berger, 
David J. Moliterno, Cleveland Clinic Foundation, Cleveland, OH, University of North 
Carolina, Chapel Hill, NC
Background: Long-term clopidogrel improves clinical outcome after PCI. We hypothe-
sized that long-term therapy may be particularly beneficial among patients developing
recurrent stenosis (restenosis).
Methods: CREDO was a randomized, double-blind, placebo-controlled trial comparing
clopidogrel pretreatment (300mg) and 1yr therapy (75mg/d), with no pretreatment and
1mth clopidogrel [control] after PCI. All patients received aspirin. The 1yr primary end-
point was a composite of death, MI, and stroke. We performed a post-hoc analysis evalu-
ating the clinical efficacy of long-term clopidogrel compared with placebo among patients
having 0, 1, or >2 revascularization procedures (ie medical therapy, index PCI only, or
index PCI and subsequent PCI or CABG).
Results: Of 1874 patients enrolled, 2.9%, 76.7%, and 16.4% had 0, 1, and >2 proce-
dures respectively. For the overall study population, the primary endpoint was signifi-
cantly reduced with long-term clopidogrel compared to control (8.5% vs 11.5%, RRR
26.9%, p=0.025). Patients who did not undergo the index PCI (medical therapy or CABG)
had no overt benefit with clopidogrel. Those who underwent only the index PCI had a
trend in primary events reduction with clopidogrel (7.7% vs 9.6%, RRR 21.7%, p=0.19).
In contrast, those requiring repeat revascularization had marked benefit with long-term
clopidogrel (15.4% vs 24.1%, RRR 42.4%, p=0.05).
Conclusions: Long-term clopidogrel after PCI particularly benefits those requiring
repeat revascularization. 
1063-55 A Pharmaco-Epidemiological Study of the Interaction 
Between Atorvastatin and Clopidogrel Following 
Percutaneous Coronary Interventions
James Brophy, Vania Costa, Mohan Babapulle, McGill University Health Center, 
Montreal, PQ, Canada
Background: Clopidogrel is commonly used following PCI to prevent thrombotic compli-
cations. A theoretical concern has been raised that atorvastatin by inhibition of the
CYP3A4 enzyme may competitively inhibit the metabolism of the prodrug clopidogrel
potentially negating these benefits. However, no clinical studies have tested this hypothe-
sis.
Methods: Using the computerized administrative databases from the Province of
Québec, we identified all patients who had PCI between 1998 and 2000, survived until
hospital discharge and received a prescription for clopidogrel within 7 days of a PCI. The
relative risk (RR) of the composite endpoint of death, hospitalizations due to myocardial
infarction or unstable angina, repeat revascularization procedures and stroke during the
next 30 days was compared between patients receiving and not receiving a prescription
for atorvastatin concomitantly. Rates were adjusted by a multivariate logistic regression
model for other medications, disease severity, associated comorbidities and demo-
graphic variables.
Results: There were 3,545 patients included in the analysis, 858 exposed and 2,687 not
exposed to atorvastatin. Adjusted 30 day RR were increased to 2.04 (95% CI 1.29 , 3.23)
in patients prescribed atorvastatin with clopidogrel compared to those not prescribed
atorvastatin. Other CYP3A4 inhibitors (RR 1.85, 95% CI 1.28, 2.69), male gender (RR
1.57, 95% CI 1.04, 2.35), previous MI (RR 1.67, 95% CI 1.16, 2.41), and heart failure
(RR 2.53, 95% CI 1.17 , 5.47) were also associated with increased risks while the use of
aspirin or ticlopidine (RR 0.61, 95% CI 0.41, 0.91) was protective. Limiting the analysis to
only patients receiving both clopidogrel and statins again showed an increased risk with
atorvastatin (RR 1.98, 95% CI 1.22, 3.21).
Conclusion: An association between the concomitant use of atorvastatin and clopidogrel
and adverse cardiovascular events following PCI has been found. The significance of this
putative interaction merits further study.
1063-56 A Randomized Comparison of Cilostazol Versus 
Clopidogrel After Coronay Stenting: The Preliminary 
Results
Seong-Wook Park, Seung-Whan Lee, Young-Hak Kim, Ki Hoon Han, Jung-Sook Auh, 
Cheol Whan Lee, Myeong-Ki Hong, Jae-Joong Kim, Seung-Jung Park, Asan Medical 
Center, Seoul, South Korea
Background: Although cilostazol, cyclic adenosine monophosphate phosphodiesterase
inhibitor, is used to prevent subacute stent thrombosis, its safety and efficacy have not
been compared with clopidogrel in a randomized manner.
Methods: Patients (n=651) who underwent coronary stenting were randomly assigned to
receive cilostazol (n=325, 477 lesions) or clopidogrel (n=326, 495 lesions) in addition to
200 mg aspirin. Loading dose (cilostazol 200mg or clopidogrel 300mg) was adminis-
trated immediately after coronary steniting. Study drugs were given for one month (cil-
ostazol 100mg bid or clopidogrel 75mg qd). The primary end point consisted of subacute
stent thrombosis or major adverse cardiac events (death, myocardial infarction, repeat
intervention) within 30 days. The secondary end points were peripheral vascular compli-
cation, major bleeding, and any adverse events (neutropenia, thrombocytopenia, skin
rash, liver dysfunction, and gastrointestinal trouble) requiring termination of study drugs
during treatment period.
Results: Study patients included 83 patients (12.7%) with primary stenting for acute
myocardial infarction. Subacute stent thrombosis occurred in 2 patients (0.6%) of cilosta-
zol group and 2 patient (0.6%) of clopidogrel group (p=0.99). Four deaths occurred dur-
ing follow-up in 2 patients (0.6%) of cilostazol group and 2 patient (0.6%) of clopidogrel
group (p=0.99). The primary end point was reached in 1.5% of cilostazol group and 1.5%
of clopidogrel group (p=0.99). The bleeding and vascular complication was seen in 0.6 %
of cilostazol group and 0.3% of clopidogrel group. Serious hematologic complications
were not observed in the two groups. Study drug-related side effects requiring cessation
of study drugs were not statistically different between two groups (0.6 % vs. 0.3 %,
p=0.56).
Conclusions: Preliminary results of this ongoing study show that the regimen with cil-
ostazol and aspirin appears to be safe and as effective as clopidogrel and aspirin in pre-
venting thrombotic complication after coronary stenting.
1063-57 Baseline Platelet Count Correlates With Ischemic 
Events and Mortality at Follow-Up After Percutaneous 
Coronary Intervention
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Mazullah Kamran, Warren Sherman, Samin K. Sharma, Mount Sinai School of Medicine, 
New York, NY
Background: Role of baseline platelet count and outcome after PCI has not been well
established. It is possible that higher baseline platelet count may be associated with
increased ischemic complications.
Methods: We analyzed 4,232 consecutive patients who had PCI between July 1999 and
July 2002 from the database for peri-procedural events and survival at 365-days. Throm-
bocytopenic patients (platelet <150,000) were excluded from the study.
The remaining patients were divided into two groups: Normal platelet count group
(n=3,735) and high platelet count group (platelet count > 320,000, 90th percentile,
n=497).
Results: There were no differences in procedural, clinical success, minor complications,
or CKMB release between the two groups. The maximum ACT modestly correlated with
the platelet count (r=-0.1, p<0.0001).The incidence of stent thrombosis was higher in
patients with high platelet count compared to normal platelet count(0.6% vs.0.1%;
p<0.02). But, there was no difference noted in target vessel revascularization on follow-
up. The platelet count correlates with risk of stent thrombosis (c-statistic=0.68;p=0.0014).
Patients with high platelet count have a higher 365-day mortality (normal platelet: 1.3%;
high platelet: 3.2%; Hazard Ratio 2.5 [1.3,4.5], p=0.0002). This difference persisted
regardless of whether glycoprotein IIb/IIIa was used (p=0.0074). Proportional hazard
model adjusting for age, hemoglobin, clinical syndrome, creatinine, liver disease, diabe-
tes, use of Glycoprotein IIb/IIIa inhibitors and age shows that high platelet count strongly
predicts higher 365-day mortality (hazard ratio 3.2 [1.2, 4.7], p=0.03).
Conclusion: Baseline elevated platelet count is an independent predictor of long term
survival after PCI, perhaps partly related to increased risk of stent thrombosis and short
term MACE. Therefore, lifelong use of oral dual antiplatelet therapy may be indicated in
this high risk subgroup post PCI.
